# Cresilon closes $25 million Series A-4 financing

Cresilon, Inc. completed a $25 million Series A-4 financing round to accelerate global expansion, increase production capacity at its Brooklyn biomanufacturing facility, and support entry into the human health market.

- Type: Investment
- Announced: 2022-10-27
- Where: Brooklyn, New York, United States
- Value: $25.0M
- Status: announced
- Products: hemostatic gel, VETIGEL
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Cresilon](https://endata.com/companies/66179.md)
- [Paulson Investment Company](https://endata.com/companies/66182.md) (investor)

## Sources

- [cresilon.com](https://cresilon.com/2022/10/27/cresilon-closes-25-million-in-series-a-4-financing-to-accelerate-global-expansion-and-bring-revolutionary-hemostatic-gel-to-human-health-market/), 2022-10-27: "The financing will support the company’s efforts to aggressively accelerate its global expansion plan and bring its revolutionary hemostatic gel to the human health market."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.